



NDA 21-684

Serono, Inc.
Attention: Pamela Williamson Joyce
Vice President, Regulatory Affairs
One Technology Place
Rockland, MA 02370

Dear Ms. Williamson Joyce:

Please refer to your new drug application (NDA) dated May 23, 2003, received May 27, 2003, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Gonal-f[®] RFF Pen (follitropin alfa injection).

We also acknowledge your submissions dated March 25, 2004, constituting a complete response to our Not Approvable letter dated November 25, 2003.

We acknowledge receipt of your submissions dated April 19 (2), 22 (2), May 17 (2), 21, and 25 (2), 2004.

This new drug application provides for the use of Gonal-f[®] RFF Pen (follitropin alfa injection) for the induction of ovulation and pregnancy in the oligo-anovulatory infertile patient in whom the cause of infertility is functional and not due to primary ovarian failure and the development of multiple follicles in the ovulatory patient participating in an Assisted Reproductive Technology (ART) program.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the attached labeling (package insert and patient package insert) and the container/carton labeling submitted on May 25, 2004. Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission “**FPL for approved NDA 21-684.**” Approval of this submission by FDA is not required before the labeling is used.

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We are waiving the pediatric study requirement for this application.

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

Please submit one marketing package of the drug product when it is available.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Archana Reddy, M.P.H., Regulatory Project Manager, at (301) 827 - 4260.

Sincerely,

{See appended electronic signature page}

Daniel Shames, M.D.
Division Director
Division of Reproductive and Urologic Drug
Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

Enclosure

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Daniel A. Shames
5/25/04 05:53:14 PM